IP Library › Granted Patent US 9,115,403
Granted Patent B2
US 9,115,403 · App. 13/254,610 · Granted Aug 25, 2015

Diagnostic method using PALB2

Inventors: Bert Vogelstein (Baltimore, MD); Kenneth W. Kinzler (Baltimore, MD); D. Williams Parsons (Ellicott City, MD); Sian Jones (Baltimore, MD); Scott Kern (Hunt Valley, MD); Ralph Hruban (Baltimore, MD); James R. Eshleman (Lutherville, MD); Michael Goggins (Baltimore, MD); Alison Klein (Baltimore, MD); Manuel Hidalgo (Baltimore, MD); Victor E. Velculescu (Dayton, MD)
C12Q1/6886G01N33/57438C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,115,403
App. No.
13/254,610
Granted
Aug 25, 2015
Kind
B2
Abstract

The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.

Claims (9)

1. A method of administering a therapy to a human with a pancreatic cancer, comprising:

testing and detecting in a sample obtained from the human with a pancreatic cancer the presence of a mutation in the PALB2 gene selected from the group consisting of: 172-5 del TTGT; IVS5-1 G>T; 3116 del A; 3256 C>T, IVS10+2 C>T; and

administering to said human a therapy that induces DNA damage or interferes with DNA damage repair in tumor cells.

2. The method of claim 1 wherein said therapy is radiation therapy.

3. The method of claim 1 wherein said therapy is a DNA damaging agent.

4. The method of claim 1 wherein said therapy is an inhibitor of a DNA repair enzyme.

5. The method of claim 1 wherein said therapy comprises treatment with a PARP inhibitor.

6. The method of claim 1 wherein said sample is a normal tissue sample.

7. The method of claim 1 wherein the human has a family history of pancreatic cancer.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 12, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044836/0524 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2012
From: VOGELSTEIN, BERT; KINZLER, KENNETH W.; PARSONS, D. WILLIAMS; JONES, SIAN; KERN, SOTT; HRUBAN, RALPH; ESHLEMAN, JAMES R.; GOGGINS, MICHAEL; KLEIN, ALISON; HIDALGO, MANUEL; VELCULESCU, VICTOR E.
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 027560/0206 →
Continuity (3)
Provisional Application 61157700 · Mar 5, 2009
Provisional Application 61264019 · Nov 24, 2009
Related Publication 20120034318A1 · Feb 9, 2012